ArticleFrontiers in neurology
Global, regional, and national burden of encephalitis from 1990 to 2021: result from the global burden of disease study 2021.
Article in Frontiers in neurology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Encephalitis is a life-threatening neurological disease with a major impact on global public health. This study uses the Global Burden of Disease 2021 (GBD 2021) data to assess the disease burden of encephalitis and provide evidence for targeted public health interventions. Methods: This study utilized the Global Burden of Disease (GBD) 2021 data analysis platform to examine trends in the prevalence, incidence, mortality, and disability-adjusted life years (DALYs) of encephalitis from 1990 to 2021, categorizing data by sex, age, and socio-demographic index (SDI). Dynamic patterns were analyzed at global, regional, and national levels. The Joinpoint Regression Program aided comparative analysis by examining annual percentage change (APC) and identifying significant turning points. Spearman's rank correlation analysis quantified associations between the encephalitis burden and SDI. Results: From 1990 to 2021, global trends in encephalitis showed declines in prevalence, incidence, mortality, and DALYs. During this period, males had a higher age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) than females. Notably, children under five experienced the highest ASIR and age-standardized disability-adjusted life-year rate (ASDR), whereas individuals aged 95 and older had the highest ASMR. Additionally, case and age-standardized rate (ASR) varied significantly by geography, especially in lower SDI regions. At the national level, Pakistan, India, Bhutan, and Nepal faced a much higher disease burden. Finally, there was also a strong negative correlation between encephalitis ASR indicators and SDI. Conclusion: Overall, despite a declining global burden of encephalitis, significant disparities in disease burden persist across different countries and regions. This observation highlights a significant imbalance, underscoring the need for targeted public health strategies to effectively mitigate and address these disparities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.